. Author manuscript; available in PMC: 2014 Mar 15.

Published in final edited form as: Cancer. 2012 Oct 12;119(6):1140–1148. doi: 10.1002/cncr.27819

Table 5.

Comparison of trials examining survival over time

Author	Number with MBC^* (and % with de novo Stage IV)	Time Period Examined	Source	Median Survival	DFI or DRFI in model	Survival over time
Chia et al⁵	2,150 (21.4%)	1991–2001	Population- based registry	15–22 months^#	No	Improved
Dabakuyo et al³³	1459 (12%)	1982–2005	Population- based registry	Relative survival reported	No	Improved
Dawood et al¹⁶	2,091 (22.4%)	1991–2007	Single institution database	28.6 months	No	Improved^$
Dawood et al⁶	15,438 (100%)	1988–2003	Population- based registry	23 months	No	Improved
Giorodano et al⁴	834 (0%)	1974–1994	Single institution database	21 months	Yes	Not Improved^{^}
Largillier et al¹⁷	1,038 (0%)	1975–2005	Single institution database	23.1 months	Yes	Not improved
This analysis	3477 (0%)	1978–2010	Multi- institution database	20 months	Yes	Not improved overall

DFI = disease-free interval; MBC=metastatic breast cancer

MBC includes both de novo Stage IV and recurrence after operable disease;

Based on time period of recurrence, 30-day/month;

HER2 status and trastuzumab use known and included in model;

^{^}

In multivariate analysis adjusting for tumor size, nodes, stage, DFI, ER status and site of metastases, p-value =0.09. In an alternate, unstratified model including DFI, p=0.04.